|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
EE05627B1
(et)
*
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7357928B2
(en)
*
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
|
CN1652820A
(zh)
*
|
2002-04-12 |
2005-08-10 |
梅达雷克斯公司 |
使用ctla－4抗体的治疗方法
|
|
PL377091A1
(pl)
|
2002-09-06 |
2006-01-23 |
Amgen, Inc. |
Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
|
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
EP2457587A1
(en)
|
2003-06-27 |
2012-05-30 |
Amgen Fremont Inc. |
Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
KR101215218B1
(ko)
|
2003-07-22 |
2012-12-26 |
바이엘 파마 악티엔게젤샤프트 |
Ｒｇ１ 항체 및 그의 용도
|
|
EP1660537A2
(en)
|
2003-08-14 |
2006-05-31 |
Dyax Corp. |
Endotheliase-2 ligands
|
|
EP1515505A1
(en)
*
|
2003-09-12 |
2005-03-16 |
Siemens Aktiengesellschaft |
Reachability maintainance of a moving network based on temporary name identifiers
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
JP2007526455A
(ja)
*
|
2004-02-03 |
2007-09-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
|
|
AU2005225227A1
(en)
*
|
2004-03-26 |
2005-10-06 |
Pfizer Products Inc. |
Uses of anti-CTLA-4 antibodies
|
|
US7785591B2
(en)
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
|
KR20070067702A
(ko)
*
|
2004-11-04 |
2007-06-28 |
화이자 프로덕츠 인크. |
유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법
|
|
PT2620450T
(pt)
|
2005-03-08 |
2018-12-17 |
Pfizer Prod Inc |
Composições de anticorpos anti-ctla-4
|
|
BRPI0609427A2
(pt)
*
|
2005-03-23 |
2010-04-06 |
Pfizer Prod Inc |
composição farmacêutica para o tratamento de cáncer de próstata e uso de um agente de terapia hormonal e de um anticorpo, ou uma porção de ligação a antìgeno do mesmo
|
|
CA2602316A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
|
|
EP2439273B1
(en)
*
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
BRPI0611766A2
(pt)
|
2005-06-08 |
2011-12-20 |
Dana Farber Cancer Institute |
métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
|
|
BRPI0612408A2
(pt)
*
|
2005-07-07 |
2010-11-03 |
Pfizer |
terapia para tratamento de cáncer em combinação com anticorpo anti-ctla-4 e oligodesoxinucleotìdeo sintético contendo o motivo cpg
|
|
JP2009518446A
(ja)
|
2005-12-07 |
2009-05-07 |
メダレックス インコーポレーティッド |
Ｃｔｌａ−４抗体投与量漸増レジメン
|
|
CA2647282A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
WO2009016449A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Pfizer Limited |
Antibody purification process by precipitation
|
|
US20090136465A1
(en)
|
2007-09-28 |
2009-05-28 |
Intrexon Corporation |
Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
|
|
RU2373836C2
(ru)
*
|
2007-12-18 |
2009-11-27 |
Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" |
Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
|
|
US8449886B2
(en)
|
2008-01-08 |
2013-05-28 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
MX2012000851A
(es)
*
|
2009-07-20 |
2012-06-08 |
Squibb Bristol Myers Co |
Combinacion de anticuerpo de anti-antigeno 4 asociado al linfocito t citotoxico con diversos regimenes terapeuticos para tratamiento sinergistico de enfermedades proliferativas.
|
|
RU2421217C2
(ru)
*
|
2009-09-03 |
2011-06-20 |
Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) |
Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
|
|
TR201905909T4
(tr)
|
2011-04-19 |
2019-05-21 |
Pfizer |
Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
|
|
ES2572915T3
(es)
|
2011-06-02 |
2016-06-03 |
The University Of Louisville Research Foundation, Inc. |
Nanopartículas conjugadas a un agente antinucleolina
|
|
MX365139B
(es)
|
2012-03-13 |
2019-05-24 |
Hoffmann La Roche |
Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
|
|
CN105457021A
(zh)
|
2012-05-04 |
2016-04-06 |
辉瑞公司 |
前列腺相关抗原及基于疫苗的免疫治疗疗法
|
|
MX364265B
(es)
*
|
2012-08-23 |
2019-04-17 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a las proteinas 158p1d7.
|
|
JP2016500251A
(ja)
*
|
2012-12-03 |
2016-01-12 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
免疫調節Ｆｃ融合タンパク質の抗癌活性の増強
|
|
BR112016002614B8
(pt)
|
2013-08-08 |
2023-11-07 |
Hopitaux Paris Assist Publique |
Imunocitoquina e composição farmacêutica
|
|
KR102457731B1
(ko)
|
2013-08-08 |
2022-10-21 |
싸이튠 파마 |
병용 약학 조성물
|
|
MX377714B
(es)
*
|
2013-10-18 |
2025-03-11 |
Regeneron Pharma |
Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
|
|
JP6712952B2
(ja)
*
|
2014-03-31 |
2020-06-24 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
固形腫瘍悪性病変を処置するための、抗ｃｔｌａ−４抗体および／または抗ｐｄ−１抗体と組み合わせた、細菌、細菌産物、および他の免疫調節性実体の使用
|
|
SG10201809450VA
(en)
*
|
2014-05-01 |
2018-11-29 |
Anaeropharma Science Inc |
Heterogeneous polypeptide expression cassette
|
|
CA2949998A1
(en)
|
2014-05-28 |
2015-12-03 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
HRP20190881T1
(hr)
|
2014-08-28 |
2019-07-12 |
Halozyme, Inc. |
Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
|
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
CA3203273A1
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
JP6885867B2
(ja)
|
2014-12-31 |
2021-06-16 |
チェックメイト ファーマシューティカルズ， インコーポレイテッド |
組合せ腫瘍免疫療法
|
|
AR103675A1
(es)
*
|
2015-02-13 |
2017-05-24 |
Sorrento Therapeutics Inc |
Anticuerpos anti-ctla4 terapéuticos
|
|
WO2016179394A1
(en)
|
2015-05-05 |
2016-11-10 |
Malik Mohammad Tariq |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
WO2017015560A2
(en)
*
|
2015-07-22 |
2017-01-26 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind lag3
|
|
EP3337495A4
(en)
*
|
2015-08-18 |
2019-04-10 |
Mateon Therapeutics, Inc. |
USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
|
|
AU2016364889B2
(en)
|
2015-12-02 |
2024-01-04 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
EA039322B1
(ru)
*
|
2016-04-15 |
2022-01-13 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
JP7198666B2
(ja)
*
|
2016-08-26 |
2023-01-04 |
哲治 奥野 |
微小血管血流低減剤およびその利用
|
|
PT3551660T
(pt)
*
|
2016-12-07 |
2023-11-30 |
Ludwig Inst For Cancer Res Ltd |
Anticorpos anti-ctla-4 e métodos de uso dos mesmos
|
|
KR102603681B1
(ko)
|
2016-12-07 |
2023-11-17 |
아게누스 인코포레이티드 |
항체 및 이의 사용방법
|
|
CA3089768A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Oncoimmune, Inc. |
Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
US20230167177A1
(en)
*
|
2018-03-19 |
2023-06-01 |
WuXi Biologics Ireland Limited |
Novel anti-ctla-4 antibody polypeptide
|
|
CN112236522A
(zh)
|
2018-04-09 |
2021-01-15 |
查克美特制药公司 |
寡核苷酸包装到病毒样颗粒中
|
|
KR102869944B1
(ko)
|
2018-07-11 |
2025-10-15 |
액팀 테라퓨틱스, 인코퍼레이티드 |
조작된 면역자극성 박테리아 균주 및 이의 용도
|
|
CN110092826B
(zh)
*
|
2019-02-28 |
2022-04-15 |
天津大学 |
CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
|
|
WO2021238932A1
(zh)
*
|
2020-05-26 |
2021-12-02 |
百奥泰生物制药股份有限公司 |
多特异性抗体及其应用
|
|
JP7758369B2
(ja)
|
2020-07-10 |
2025-10-22 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Ｇａｓ４１阻害剤及びその使用方法
|
|
WO2022086852A2
(en)
|
2020-10-19 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|